ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Comparative analysis of immune checkpoint inhibitors in first-line treatment of esophageal squamous cell carcinoma: a network meta-analysis

Zhang, Yangfeng; Li, Chunhui; Du, Kunpeng; Pengkhun, Nov; Huang, Zijian; Gong, Min; Li, Yanyang; Liu, Xiang; Li, Lilin; Wang, Duanyu; Wang, Changqian; Chen, Fengsheng*; Li, Jiqiang*南方医科大学
Immunotherapy2023-7DOI: 10.2217/imt-2022-0236
1被引14阅读
引用收藏
分享

摘要

Aim: To evaluate the efficacy and safety of first-line immunochemotherapy in the treatment of advanced esophageal squamous cell carcinoma (CRD42021287033). Methods: PubMed, Embase, Cochrane Library and Web of Science were systematically searched to obtain randomized controlled trials, and the outcome indicators of the reports were compared and analyzed. Results: A total of 3163 patients from five reported randomized controlled trials were included in the meta-analysis. The results showed the comprehensive benefits of toripalimab combined with chemotherapy, in terms of overall survival (hazard ratio: 0.59; 95% CI: 0.43-0.81) and progression-free survival (hazard ratio: 0.58; 95% CI: 0.46-0.73). Conclusion: Toripalimab combined with chemotherapy may be a better choice for first-line immunochemotherapy, although this needs to be verified by clinical studies.

学科与关键词

关键词
advanced ESCCefficacyfirst-line treatmentimmunotherapynetwork meta-analysisrandomized controlled trialsafety
相关
加载中…
  • Efficacy and safety of immunochemotherapy, immunotherapy, chemotherapy, and targeted therapy as first-line treatment for advanced and metastatic esophageal cancer: a systematic review and network meta-analysis
    Gao, Zhen; Huang, Shujie; Wang, Sichao; Tang, Dezhao; Xu, Wei; Zeng, Ruijie; Qiao, Guibin*LANCET REGIONAL HEALTH-WESTERN PACIFIC, 2023, 38: 100841.被引 3
  • Toripalimab plus chemotherapy in treatment-naive, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial
    Wang, Zi-Xian; Cui, Chengxu; Yao, Jun; Zhang, Yanqiao; Li, Mengxia; Feng, Jifeng; Yang, Shujun; Fan, Yun; Shi, Jianhua; Zhang, Xizhi; Shen, Lin; Shu, Yongqian; Wang, Cailian; Dai, Tianyang; Mao, Teng; Chen, Long; Guo, Zengqing; Liu, Bo; Pan, Hongming; Cang, Shundong; Jiang, Yi; Wang, Junye; Ye, Min; Chen, Zhendong; Jiang, Da; Lin, Qin; Ren, Wei; Wang, Junsheng; Wu, Lin; Xu, Yong; Miao, Zhanhui; Sun, Meili; Xie, Conghua; Liu, Ying; Wang, Qifeng; Zhao, Lina; Li, Qi; Huang, Canhong; Jiang, KeCancer Cell, 2022, 40(3): 277-+.被引 139
  • Comparative efficacy and toxicity of immune checkpoint inhibitors in combination with or without chemotherapy treatment for advanced esophageal squamous cell carcinoma: A systematic review and meta-analysis
    Ma, Yue; Xin, Yu; Su, Dan; Zhou, Yuxin; Li, Hongxu; Zou, Haoyi; Yu, Xuefan; Yang, Qing; Cui, Jie; Wang, Changsong*; Zhang, Yanqiao*Frontiers in Oncology, 2022, 12: 958783.
查看全部 →

发表信息

论文状态
公开发表
期刊
Immunotherapy
发表日期
2023-07
卷期
第 15 卷, 第 10 期
页码
737-750
DOI
10.2217/imt-2022-0236
语言
ENGLISH
成果收录
SCIE
资助标注
Beijing Xisike Clinical Oncology Research Foundation [Y-QL2019-0293]; Natural Science Foundation of Guangdong Province [2023A1515012548]

作者

  • Z

    Zhang, Yangfeng (第一作者)

    southern med univ

  • L

    Li, Chunhui

    southern med univ

查看全部 13 位作者收起作者
  • D

    Du, Kunpeng

    southern med univ

  • P

    Pengkhun, Nov

    southern med univ

  • H

    Huang, Zijian

    southern med univ

  • G

    Gong, Min

    southern med univ

  • L

    Li, Yanyang

    southern med univ

  • L

    Liu, Xiang

    southern med univ

  • L

    Li, Lilin

    southern med univ

  • W

    Wang, Duanyu

    southern med univ

  • W

    Wang, Changqian

    southern med univ

  • C

    Chen, Fengsheng (通讯)

    southern med univ

  • L

    Li, Jiqiang (通讯)

    southern med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417